The project, which is an initiative of the Quest Diagnostics Foundation, aims to expand healthcare access in the area, including through no-cost laboratory testing.

The guidelines address items like interpretation of results that may be affected by gender-affirming hormone therapy and improving electronic health record practices.

The company aims to complete the international development and validation of the test, as well as to obtain European regulatory approval and commercialize it as a service and a kit.

The PCR-based panels detect up to 22 of the most common bacteria, viruses, and parasites associated with gastroenteritis.

Last week, readers were most interested in a story about Achieve Diagnostics buying the pharmacogenomic assets of H&M Molecular Diagnostics.